Placulumab has been used in trials studying the treatment of Rheumatoid Arthritis.
別名(Alternative names)
ART621,CEP-37247,PN0621
靶點;物種(Specificity target name;species)
TNFSF2/TNF-alpha/TNFA[Homo sapiens]
活性研究(體外/體內(nèi)研究)(Activity in vitro)
Adalimumab (anti-TNF-alpha) blocks the interaction of TNF with the p55 and p75 cell surface TNF receptors, thereby neutralising the activity of this cytokine. Through its anti-TNF actions, adalimumab reduces concentrations of matrix metalloproteases (MMP-1 and -3) and other markers of cartilage and synovium turnover, reduces of matrix metalloproteases (MMP-1 and -3) and other markers of cartilage and synovium turnover, and reduces concentrations of acute phase reactants of inflammation (C-reactive protein [CRP] and erythrocyte sedimentation rate [ESR]) and serum cytokines (IL-1β mRNA, IL-1 receptor antagonist, IL-6).
種類(Species)
Homo sapiens
受體鑒定(Receptor identification)
[V-kappa]2-Fc
CAS
945781-29-3
存儲條件(Storage)
Use a manual defrost freezer and avoid repeated freeze-thaw cycles.